AbbVie sees 37% drop in Humira sales this year as biosimilars hit U.S. market

Amjevita, the first biosimilar competition for Humira in the United States. At least seven others are expected to debut this summer.

Overall, Humira sales rose 4.6% to $5.58 billion, in line with estimates, lifted by growth in the U.S. market. Skyrizi sales of $1.58 billion beat analysts' estimates of $1.52 billion, while Rinvoq missed with $770 million in sales compared with expectations of $816.14 million.

Österreich Neuesten Nachrichten, Österreich Schlagzeilen